Aspirin-Mediated Mesenchymal Stem Cell Viability for Oncolytic Virus Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer treatments using oncolytic viruses face challenges such as short viability of virus-infected mesenchymal stem cells, leading to limited therapeutic window and potential side effects, and existing methods are not suitable for long-term storage or commercialization due to rapid lysis of stem cells by the virus.

Innovation Solution

Introducing an oncolytic virus into mesenchymal stem cells and treating them with aspirin to prolong virus replication time and prevent cell lysis, thereby enhancing cell viability and survival period, and storing these cells in autologous serum containing aspirin to maintain their anticancer activity during cold storage.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If an oncolytic virus is introduced into mesenchymal stem cells for cancer therapy, then the anticancer activity is enhanced through viral replication and spread, but the viability and survival period of the stem cells are significantly reduced due to rapid lysis

Engineering Contradiction:

Improveanticancer activityVSAvoidviability of stem cells

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

Aspirin is introduced as an intermediary substance that mediates between the oncolytic virus and mesenchymal stem cells. It selectively inhibits viral replication in stem cells while allowing therapeutic viral activity in cancer cells, thereby resolving the contradiction between maintaining stem cell viability and achieving anticancer efficacy

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the biochemical parameters of the system by introducing aspirin, which alters the replication dynamics of the oncolytic virus. This parameter change extends the survival period of virus-infected stem cells from a few hours to over 80 hours while preserving the virus's anticancer activity

Inventive Principle:

Principle #35Parameter changes

2Productivity

If the virus replication time is extended to improve therapeutic effect, then more cancer cells can be destroyed, but the stem cells undergo lysis and die sooner

Engineering Contradiction:

Improveanticancer efficacyVSAvoidcell survival

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

Aspirin serves as a selective mediator that differentiates the fate of virus-infected cells based on their type. It allows prolonged viral replication and enhanced anticancer efficacy while simultaneously protecting mesenchymal stem cells from lysis, thus resolving the productivity-reliability contradiction

Inventive Principle:

Principle #24Intermediary (Mediator)

3Object-affected harmful factors

If mesenchymal stem cells are used as carriers for oncolytic virus delivery, then the targeting precision and reduced side effects are improved, but the short viability window limits the therapeutic application

Engineering Contradiction:

Improveside effectsVSAvoidtherapeutic window

Core Design Contradiction:

Object-affected harmful factorsVSLoss of time

Solution Approach 1:

The introduction of aspirin changes the temporal parameters of the system, extending the therapeutic window from a short viability period to over 80 hours. This allows sufficient time for the targeted delivery of oncolytic viruses to cancer sites while maintaining the low side effect profile of stem cell carriers

Inventive Principle:

Principle #35Parameter changes

4Ease of manufacture

If the stem cells are stored for long-term use, then the commercial viability and storage capability are improved, but the rapid virus-induced lysis prevents long-term storage

Engineering Contradiction:

Improvestorage capabilityVSAvoidstorage period

Core Design Contradiction:

Ease of manufactureVSDuration of action of stationary object

Solution Approach 1:

Aspirin acts as a protective intermediary during storage, preventing virus-induced lysis of mesenchymal stem cells. This enables long-term storage of the cell-virus conjugates while maintaining their viability and therapeutic activity, thus resolving the contradiction between storage capability and storage period

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20230016479A1Method for preparing mesenchymal stem cells having improved viability through Anti-cancer virus introduction

Publication Date: 2023.01.19 R BIO CO LTD

AI summary

The present invention relates to a method for preparing oncolytic virus-containing mesenchymal stem cells having improved cell viability, a method for storing the oncolytic virus-containing stem cells produced by the method, and a cell therapeutic agent for cancer treatment containing the oncolytic virus-containing stem cells produced by the method. More particularly, an oncolytic virus is introduced into mesenchymal stem cells, followed by treatment with aspirin, so that the infection efficiency of the oncolytic virus may be increased, the replication time of the virus may be prolonged, and lysis of the stem cells by the virus may be prevented, thereby improving the viability and survival period of the stem cells and preparing anticancer stem cells having excellent activity. The anticancer stem cell therapeutic agent produced in this way is maintained at high viability during cold storage due to aspirin treatment, and thus is very useful medically and industrially.